Drug Profile
TAK 329
Alternative Names: TAK-329Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Takeda
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 31 Oct 2013 Discontinued - Phase-I for Type-1 diabetes mellitus in Japan (PO)
- 31 Oct 2013 Discontinued - Phase-I for Type-1 diabetes mellitus in USA (PO)
- 31 Jan 2012 Takeda completes a phase I trial in Type-1 diabetes mellitus in USA (NCT01311076)